{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:19:47Z","timestamp":1776370787508,"version":"3.51.2"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.pbb.2019.172842","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T08:49:47Z","timestamp":1577782187000},"page":"172842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways"],"prefix":"10.1016","volume":"189","author":[{"given":"Andrzej","family":"Wr\u00f3bel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Serefko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wo\u017aniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Kociszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Wi\u015bniewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Poleszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2019.172842_bb0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.pbb.2019.172842_bb0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0006-3223(89)90183-2","article-title":"Elevated CSF CRF in suicide victims","volume":"25","author":"Arato","year":"1989","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1176\/ajp.144.7.873","article-title":"CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia","volume":"144","author":"Banki","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00192-012-2027-1","article-title":"Biomarkers in overactive bladder","volume":"24","author":"Bhide","year":"2013","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.pbb.2019.172842_bb0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/mp.2009.141","article-title":"The CRF system, stress, depression and anxiety-insights from human genetic studies","volume":"15","author":"Binder","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0090-4295(03)00590-9","article-title":"Serotonergic modulation of bladder afferent pathways","volume":"62","author":"Burgard","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.pbb.2019.172842_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000447034","article-title":"The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature","volume":"85","author":"Carvalho","year":"2016","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.pbb.2019.172842_bb0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0022-5347(17)55023-5","article-title":"Imipramine\u2014a possible alternative to current therapy for urinary incontinence in the elderly","volume":"125","author":"Castleden","year":"1981","journal-title":"J. Urol."},{"key":"10.1016\/j.pbb.2019.172842_bb0045","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1176\/ajp.150.4.656","article-title":"Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression","volume":"150","author":"De Bellis","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.pbb.2019.172842_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WNF.0b013e3182613dce","article-title":"Duloxetine for the treatment of overactive bladder syndrome in multiple sclerosis: a pilot study","volume":"35","author":"Di Rezze","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.pbb.2019.172842_bb0060","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1749-6632.1996.tb15114.x","article-title":"Postmortem and cerebrospinal fluid studies of corticotropin-releasing factor in humans","volume":"780","author":"Hartline","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.pbb.2019.172842_bb0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00213-010-2120-4","article-title":"The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs","volume":"215","author":"Hassanzadeh","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172842_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1520-6394(1998)8:2<71::AID-DA5>3.0.CO;2-N","article-title":"Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment","volume":"8","author":"Heuser","year":"1998","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.pbb.2019.172842_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.urology.2012.04.019","article-title":"Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study","volume":"80","author":"Hirayama","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.pbb.2019.172842_bb0080","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","article-title":"Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis","volume":"71","author":"Howren","year":"2009","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.pbb.2019.172842_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.03.083","article-title":"Bladder defense molecules, urothelial differentiation, urinary biomarkers, and interstitial cystitis","volume":"69","author":"Hurst","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.pbb.2019.172842_bb0090","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.pbb.2019.172842_bb0095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5498\/wjp.v6.i3.283","article-title":"Neuroinflammation and cytokine abnormality in major depression: cause or consequence in that illness?","volume":"6","author":"Jeon","year":"2016","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.autneu.2005.08.003","article-title":"The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat","volume":"123","author":"Klausner","year":"2005","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.pbb.2019.172842_bb0105","first-page":"R692","article-title":"Expression of corticotropin-releasing factor and CRF receptors in micturition pathways after cyclophosphamide-induced cystitis","volume":"291","author":"LaBerge","year":"2006","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.pbb.2019.172842_bb0110","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12894-016-0179-x","article-title":"The relationship between depression and overactive bladder\/urinary incontinence symptoms in the clinical OAB population","volume":"16","author":"Lai","year":"2016","journal-title":"BMC Urol."},{"key":"10.1016\/j.pbb.2019.172842_bb0115","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1464-410X.2009.08380.x","article-title":"Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder","volume":"103","author":"Liu","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.pbb.2019.172842_bb0120","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/nau.21118","article-title":"Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy","volume":"30","author":"Liu","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.pbb.2019.172842_bb0125","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0022-5347(17)38976-0","article-title":"Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study","volume":"142","author":"Lose","year":"1989","journal-title":"J. Urol."},{"key":"10.1016\/j.pbb.2019.172842_bb0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00192-011-1641-7","article-title":"Solifenacin for overactive bladder: a systematic review and meta-analysis","volume":"23","author":"Luo","year":"2012","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.pbb.2019.172842_bb0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/nau.23277","article-title":"Severe depression and anxiety in women with overactive bladder","volume":"37","author":"Melotti","year":"2018","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.pbb.2019.172842_bb0140","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1523\/JNEUROSCI.4734-03.2004","article-title":"Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region","volume":"24","author":"Merali","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pbb.2019.172842_bb0145","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00213-014-3475-8","article-title":"High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression","volume":"231","author":"Mikoteit","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172842_bb0150","first-page":"1","article-title":"Direct and indirect evidences of BDNF and NGF as key modulators in depression: role of antidepressants treatment","author":"Mondal","year":"2018","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.pbb.2019.172842_bb0155","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pbb.2019.172842_bb0160","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1126\/science.6334362","article-title":"Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients","volume":"226","author":"Nemeroff","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.pbb.2019.172842_bb0165","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.pbb.2008.02.020","article-title":"Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression","volume":"89","author":"Overstreet","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pbb.2019.172842_bb0170","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.pbb.2019.172842_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121883","article-title":"Serotonin and noradrenaline reuptake inhibitors improve micturition control in mice","volume":"10","author":"Redaelli","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2019.172842_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archpsyc.58.5.445","article-title":"Cytokine-associated emotional and cognitive disturbances in humans","volume":"58","author":"Reichenberg","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpsychires.2014.04.021","article-title":"Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity","volume":"55","author":"Schmidt","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0190","doi-asserted-by":"crossref","first-page":"F1663","DOI":"10.1152\/ajprenal.00523.2013","article-title":"Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats","volume":"305","author":"Schwen","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.pbb.2019.172842_bb0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5213\/inj.1732652.326","article-title":"Evaluation of overactive bladder in male antidepressant users: a prospective study","volume":"21","author":"Solmaz","year":"2017","journal-title":"Int. Neurourol. J."},{"key":"10.1016\/j.pbb.2019.172842_bb0200","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1464-410X.2007.06980.x","article-title":"Duloxetine compared with placebo for treating women with symptoms of overactive bladder","volume":"100","author":"Steers","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.pbb.2019.172842_bb0205","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbr.2009.09.003","article-title":"Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress","volume":"206","author":"Stemmelin","year":"2010","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.biopsych.2014.01.008","article-title":"Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial","volume":"76","author":"Su","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172842_bb0215","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s11064-019-02891-5","article-title":"A selective M1 and M3 receptor antagonist, penehyclidine hydrochloride, exerts antidepressant-like effect in mice","volume":"44","author":"Sun","year":"2019","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0220","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat","volume":"274","author":"Thor","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pbb.2019.172842_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(93)90002-X","article-title":"Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects","volume":"46","author":"Veith","year":"1993","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0230","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpsychores.2014.11.019","article-title":"Affective symptoms and the overactive bladder - a systematic review","volume":"78","author":"Vrijens","year":"2015","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11255-013-0540-x","article-title":"Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder","volume":"46","author":"Wang","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.pbb.2019.172842_bb0240","doi-asserted-by":"crossref","first-page":"212","DOI":"10.9758\/cpn.2015.13.2.212","article-title":"Overactive bladder successfully treated with duloxetine in a female adolescent","volume":"13","author":"Wang","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.pbb.2019.172842_bb0245","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1017\/S1461145702003103","article-title":"The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans","volume":"5","author":"Wichers","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2019.172842_bb0250","series-title":"Depression and Other Common Mental Disorders","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.pbb.2019.172842_bb0255","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbi.2004.10.003","article-title":"Acute inflammation and negative mood: mediation by cytokine activation","volume":"19","author":"Wright","year":"2005","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.pbb.2019.172842_bb0260","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/nau.22978","article-title":"The effect of combined treatment with a beta3 AR agonist and a ROCK inhibitor on detrusor overactivity","volume":"36","author":"Wr\u00f3bel","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.pbb.2019.172842_bb0265","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/nau.22918","article-title":"The influence of Rho-kinase inhibition on acetic acid-induced detrusor overactivity","volume":"36","author":"Wr\u00f3bel","year":"2017","journal-title":"Neurourol. Urodyn."},{"key":"10.1016\/j.pbb.2019.172842_bb0270","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00192-016-3027-3","article-title":"Fourteen-day administration of corticosterone may induce detrusor overactivity symptoms","volume":"27","author":"Wrobel","year":"2016","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.pbb.2019.172842_bb0275","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejphar.2017.07.010","article-title":"SN003, a CRF1 receptor antagonist, attenuates depressive-like behavior and detrusor overactivity symptoms induced by 13-cis-retinoic acid in rats","volume":"812","author":"Wrobel","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172842_bb0280","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00192-017-3424-2","article-title":"The influence of duloxetine on detrusor overactivity in rats with depression induced by 13-cis-retinoic acid","volume":"29","author":"Wr\u00f3bel","year":"2018","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.pbb.2019.172842_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejphar.2018.08.027","article-title":"Inhibition of Rho kinase by GSK 269962 reverses both corticosterone-induced detrusor overactivity and depression-like behaviour in rats","volume":"837","author":"Wrobel","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172842_bb0290","first-page":"10","article-title":"Blebbistatin, a myosin II inhibitor, exerts antidepressant-like activity and suppresses detrusor overactivity in an animal model of depression coexisting with overactive bladder","author":"Wrobel","year":"2018","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.pbb.2019.172842_bb0295","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.npp.1301029","article-title":"The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters","volume":"31","author":"Zhu","year":"2006","journal-title":"Neuropsychopharmacology"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719305295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719305295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:36:17Z","timestamp":1758774977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305719305295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":59,"alternative-id":["S0091305719305295"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172842","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duloxetine reverses the symptoms of overactive bladder co-existing with depression via the central pathways","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"172842"}}